GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Naureen Quibria - Capital One Securities Edward White - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Investor and Analyst [indiscernible] Please note this event is being recorded. Today's remarks will be followed by a que ...

Exhibit 99.2 Forward-Looking Statements GlycoMimetics GlycoMimetics Transforming Lives Glycobiology-based Therapeutics May 2024 | NASDAQ: GLYC To the extent that statements contained in this presentation are not descriptions of historical facts, thr statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. | "us," or "our"). Forward-looking statements contained in this presentation may include, but are not lin or projected timing of events, data readout and data ana ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Bruce Johnson - Chief Commercial Officer Brian Hahn - CFO Conference Call Participants Tara Bancroft - TD Cowen Naureen Quibria - Capital One Securities Edward White - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this tim ...

EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 ROCKVILLE, Md.--(BUSINESS WIRE) – March 27, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million. "With t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporation or organization) 9708 Medical Center Drive Rockville, Maryland 20850 (Address of principal executive offices) ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. Following manage ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (Stat ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - CMO Brian Hahn - CFO Conference Call Participants Roger Song - Jefferies Operator Good morning, and thank you for joining the GlycoMimetics, Q2 2023 Earnings Call. At this time all participants are in listen-only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions]. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR (I.R.S. Employer Identification No.) (240) 243-1201 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Registrant's telephone number, i ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants Harout Semerjian - CEO Brian Hahn - CFO Edwin Rock - CMO Christian Dinneen-Long - General Counsel Conference Call Participants Roger Song - Jefferies Steve Bersey - H.C. Wainwright & Co. Operator Good morning, and thank you for joining the GlycoMimetics Q1 2023 Earnings Call. At this time, all participants are in listen-only mode. Following the management’s remarks, we will hold a question-and-answ ...